Comparative vitro activity new quinolone fleroxacin respiratory pathogens patients cystic fibrosis fleroxacin fluoroquinolone isolates sputum patients cystic fibrosis isolates rough mucoid Pseudomonas aeruginosa Pseudomonas cepacia Staphylococcus aureus Haemophilus influenzae Escherichia coli isolates broth microdilution method influence various pHs inoculum sizes biological fluids serum sputum patients cystic fibrosis Fleroxacin MICs isolates aeruginosa micrograms/ml cepacia micrograms/ml aureus microgram/ml influenzae micrograms/ml coli micrograms/ml Fleroxacin activity mucoid aeruginosa similar activities enoxacin ofloxacin ciprofloxacin active norfloxacin enoxacin active ciprofloxacin ofloxacin aureus Fleroxacin inhibitory activity cepacia two- ciprofloxacin quinolones Alterations pH diluent inoculum size affect fleroxacin activity results available pharmacokinetic tissue distribution data support need clinical evaluation fleroxacin pulmonary infections patients cystic fibrosis 